| Name | Title | Contact Details |
|---|
At VSP Global, we activate the full power of care by consciously reinvesting in greater vision, health, and opportunities for all. Our mission is to help people see every possibility—and we do that through our strategic business pillars that work together to connect nearly 90 million patients to network doctors in a variety of settings across the globe. When you become a VSPeep, you join a group of thinkers, doers, adventurers, risk-takers, and boundary pushers who think outside the peripheral to develop products, programs, and services that help create a world where everyone can bring their best vision to life. The VSP Global Values are: We care, We trust, We empower diversity, and We are one team. Join the power of our purpose and check out job opportunities with VSP Global and its strategic businesses, including: VSP Vision Care, Marchon Eyewear, Altair Eyewear, VSP Optics, Eyefinity EHR, VSP Retail, VSP Ventures, and Eyes of Hope (our charitable giving platform).
Health Professionals and Allied Employees - AFT/AFL-CIO is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sierra Health Services is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Falck A/S is a Nordic-based organization with activities in most areas of Europe and representation on five continents.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.